Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability for GLP-1 therapy and expanding access to advanced diabetes treatment for patients. For many patients, the decision to start advanced injectable therapy is often delayed due to cost and complexity. By significantly improving affordability, GLIPIQ aims to expand access to GLP-1 therapy and enable earlier treatment initiation across a broader patient population.

GLIPIQ is available in both vial and pre-filled pen formulations. The product has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India, demonstrating favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes. At the core of GLIPIQ is its vial-based formulation with dose-specific syringes, designed to enable a more accessible, flexible, and clinically manageable approach to GLP-1 therapy. The expected weekly cost of treatment with GLIPIQ vials range from Rs 325 to Rs 440, significantly lowering the cost barrier to initiate GLP-1 therapy in India and establishing a more affordable entry point into this class of treatment.

In addition to vials, GLIPIQ is also available in pre-filled pen format, offering convenience of self-dosing for long-term therapy. Together, the two formats - vial and pen - enable a structured treatment pathway. This approach supports continuity of care, improved adherence, and sustained treatment outcomes. Both presentations are available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL. The company is also introducing ‘Sankalp’, a patient support program (PSP) designed to support therapy initiations, improve comfort with injectable treatment, and enable long-term adherence.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.